HSIL case: HPV‑negative note
A cytopathologist shared a SurePath slide of HSIL with glandular involvement in a 30‑year‑old, illustrating high‑grade nuclear changes on cervical cytology despite no immediate HPV context given in the post (x.com). The thread included cytology images and reached roughly 714 views with multiple likes and reposts in the past two days (x.com).
A Pap test looks for abnormal cells on the cervix, and one high-grade result can point to a precancer even before any human papillomavirus test result is in view. (cancer.gov) High-grade squamous intraepithelial lesion, or HSIL, is the Pap test term for cells that look much more abnormal than a low-grade change and are linked to a higher risk of cervical precancer. The Bethesda reporting system uses HSIL as a standard category in cervical cytology. (pmc.ncbi.nlm.nih.gov) “Glandular involvement” means the squamous precancer appears to extend into the glands of the cervix, which can complicate how the cells look on a slide and how pathologists describe them. A study on endocervical gland involvement said that finding can affect clinical management. (pmc.ncbi.nlm.nih.gov) The slide in this case was prepared with SurePath, a liquid-based Pap method that suspends cervical cells in fluid before they are processed onto a glass slide. The National Cancer Institute lists liquid-based tests such as ThinPrep among modern cervical screening technologies used alongside Pap cytology and human papillomavirus testing. (cancer.gov) For a 30-year-old in the United States, current screening guidance generally relies on primary human papillomavirus testing, cotesting, or cytology alone depending on the setting, but abnormal results are managed under American Society for Colposcopy and Cervical Pathology risk-based guidelines. The American College of Obstetricians and Gynecologists says screening begins at 21, and the American Cancer Society says average-risk screening now starts at 25. (acog.org) (cancer.org) Those management guidelines treat HSIL cytology as a high-risk result. The American Society for Colposcopy and Cervical Pathology says its current recommendations are risk-based and cover abnormal screening results across cytology, human papillomavirus testing, and cotesting. (asccp.org) An HPV-negative note does not automatically cancel out a high-grade Pap result. A recent tertiary-center study of HPV-negative HSIL or atypical squamous cells-cannot exclude HSIL found that some patients still had cervical intraepithelial neoplasia grade 2 or worse on biopsy. (pmc.ncbi.nlm.nih.gov) False-negative screening results can happen for several reasons, including sampling limits, slide interpretation issues, and lesions that are missed by the test used first. A review of cervical cancer screening false negatives said both cytology and triage methods can miss disease. (pmc.ncbi.nlm.nih.gov) That is why follow-up after an abnormal Pap matters more than any single screenshot of a slide. The National Cancer Institute says most abnormal cervical screening results are not cancer, but patients should get the follow-up care their clinician recommends. (cancer.gov)
